GLPG

Galapagos NV

Biotechnology

Profit on This Biotech-Enabler That’s Suddenly a “Buy”

by

"Lead, follow, or get out of the way."

This is one of those well-known aphorisms that's been around forever – though its originator is unknown.

Truth be told, it doesn't matter who said it first. It's a great bit of advice.

Especially as we interpret it.

In our investment work here at Money Morning, we always seek to lead Wall Street and the rest of the packrat investment crowd.

We never follow, especially since "the crowd" tends to be indecisive, late to the gun – or flat out wrong.

And we always get out of the way – sidestepping the dust-rising thump that's an inevitable result of the miscues and sins of the Wall Street Goliath.

It's a simple formula. And a successful one.

And it's the reason we keep outperforming "the crowd."

Like the 2,067% gain on biotech Galapagos NV, the very first stock I recommended on the very first day I published my Member-based service, Private Briefing, back in August 2011.

My readers also pulled down peak gains of more than 2,892% in Nvidia, 2,828% in Advanced Micro Devices, 818% in biotech buyout Pharmacyclics, and more.

Today, I've decided to share my latest insight on one of my big biotech winners with Money Morning readers because the opportunity is too good to keep to ourselves. And since my colleague Michael Robinson recently talked about 2020's record-crushing biotech IPOs, it's the perfect time to share this.

The company I'm showing you today is essential to biotech stocks. It's a "biotech-enabler" that's zoomed 1,755% since I first told my readers about it back in June 2013.

In 2013, it was trading at $8.14.

It closed July 30 at $151.25 – not long after Investor's Business Daily said the stock had entered a "Buy Zone."

True, but where were they seven years and 1,755% ago?

Of course, what's important now is what comes next – and it's clear this stock's run isn't over… Full Story

Stocks

This Deal Could Put You Up Much More Than 149%

by

It was the very first stock that I recommended on the very first day we published Private Briefing nearly eight years ago…

I've re-recommended the shares to my readers several times, and when something happened that I felt everyone should know about, we made sure to get the news out in Money Morning, too.

When I first wrote about it in 2011, shares were trading at $8.60. As of Wednesday morning, the stock was sitting near all-time highs at $171 – monumental gains of nearly 1,900%.

But I'm writing today because it's been a big winner for you, too – more than 149%.

And I don't think it's done, not by a long shot…

Let me tell you about the company - and all about this latest development...

biotech

A New "Super Drug" Will Send This Biotech Stock Skyrocketing

by

One of the biggest waves in healthcare now is the care and treatment of the aging population. Among the more common maladies we face as we get older is arthritis – and specifically rheumatoid arthritis (RA).

It's big deal, too. RA the third most common type of arthritis behind osteoarthritis and gout. And it affects over 1.3 million Americans and up to 1% of the world's population.

Fortunately, a small biotech company revealed last week that, along with its partner, its new drug to help combat rheumatoid arthritis reached its test goals in its phase 3 study. The stage is now set for a "new drug application" for U.S. Food and Drug Administration approval.

This drug has the potential to bring incredible gains for today's biotech stock...

Stocks

Every Stock on This List Will Triple the S&P 500's Returns

by

Here at Money Morning, we work with a team of 11 investing and market professionals who've invested real money for themselves and others over the decades they've spent in their respective fields.

In fact, as a group, these folks have close to 300 years of boots-on-the-ground experience in energy markets, global investing, precious metals and resources, technology investing and venture capital, and trading.

They've been brokers, traders, educators, engineers, soldiers, scientists, journalists, venture capitalists, government consultants, diplomats – a huge breadth of experience – and now they work for you to help make your investing more profitable.

And their recommendations have been profitable indeed.

Here are 10 of their very best picks. We always say we'll put our editors' research up against Wall Street's best anytime, and you'll see in a minute that these stocks have crushed the S&P 500's returns over the same time frame.

Here are three of the best, and you'll get a chance to check out the entire list a little further down - there's still a lot of upside left to run...

Biotechnology

Our "War on Pain" Biotech Put You Up by Double Digits in Just Two Weeks

by

Insys Therapeutics – our "War on Pain" biotech play – has given us a profit of more than 10.7% since we recommended the stock a little less than two weeks ago.

I hope you like profits, because that's just for starters.

The U.S. Food and Drug Administration (FDA) last week approved the final "product label" for the company's new synthetic marijuana drug – which means Insys can bring this new therapy to market in August.

Investors who specialize in drug stocks are always trying to pull profits from trades based on the three-step FDA "phalanx" that up-and-coming biotechs must navigate to finally get a new drug to market.

But if you really want to cash in, commercialization is the "triggering event" that can make that happen.

And that's exactly where Insys is right now.

Let me give you a little bit of context here - before I explain exactly what's going to happen next...